Walsh has been chairing the company’s board of directors since March 2018 and will continue as chair. He will succeed Carol Burns as CEO.
“Cagent Vascular is an exceptional company with a disruptive technology platform and a highly talented team,” Walsh said in a news release. “It is a privilege to lead this company through the next phase of growth. Our focus in the weeks, months, and years ahead will be on driving superior execution as we scale up and realize further market adoption.”
Prior to joining the company, Walsh was the head of Carl Zeiss Meditech Cataract Technology. He has also been the President and CEO of IanTECH Medical, which was acquired by Carl Zeiss Meditech, and Transcend Medical. Walsh has more than 25 years of medical device and healthcare industry experience in marketing, sales, and executive leadership.
“Brian Walsh’s tenure as Chairman of the Board and previous executive leadership positions give him the perfect vantage point from which to take the company forward. The board is dedicated to working with Brian and team to accelerate market adoption of Serranator and help elevate the patient care journey. On behalf of the board, I thank Carol for her significant contributions both as co-founder and as CEO over the past 10 years,” Marc-Andre Marcotte, a Cagent Vascular board member and Partner at Sectoral Asset Management, said.
